“Inotersen was negative in an adequate standard battery of in vitro (Ames, chromosomal aberration in Chinese hamster lung cells) and in vivo (CD-1 mouse micronucleus at single doses up to 2000 mg/kg SC) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Carcinogenicity
26-week rasH2 mouse (inotersen + surrogate) negative; 2-year rat study as postmarketing requirement
“In transgenic (TgRasH2) mice, subcutaneous administration of inotersen (0, 10, 30, or 80 mg/kg) or a species-specific surrogate (ISIS 401724; 30 mg/kg) weekly for 26 weeks resulted in no drug-related increase in tumors.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Reproductive & developmental
Full battery in mouse (FEED/EFD, PPND, with surrogate) and rabbit EFD; only reduced fetal weight at rabbit high dose
“A full battery of reproductive and development studies was conducted in CD-1 mouse and New Zealand White rabbit.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
“No adverse effects of inotersen were observed on a core battery of safety pharmacology parameters in CNS in CD-1 mouse (CNS) or cynomolgus monkey (cardiovascular and respiratory) following acute SC doses of up to 300 or 40 mg/kg, respectively.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗